Cover Page
Cover Page - shares | 3 Months Ended | |
Jul. 31, 2023 | Aug. 29, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jul. 31, 2023 | |
Document Transition Report | false | |
Entity File Number | 0-5286 | |
Entity Registrant Name | KEWAUNEE SCIENTIFIC CORPORATION | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 38-0715562 | |
Entity Address, Address Line One | 2700 West Front Street | |
Entity Address, City or Town | Statesville, | |
Entity Address, State or Province | NC | |
Entity Address, Postal Zip Code | 28677-2927 | |
City Area Code | 704 | |
Local Phone Number | 873-7202 | |
Title of 12(b) Security | Common Stock, $2.50 par value | |
Trading Symbol | KEQU | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 2,904,094 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2024 | |
Document Fiscal Period Focus | Q1 | |
Entity Central Index Key | 0000055529 | |
Current Fiscal Year End Date | --04-30 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Jul. 31, 2023 | Jul. 31, 2022 | |
Income Statement [Abstract] | ||
Net sales | $ 49,839 | $ 50,123 |
Cost of products sold | 37,925 | 43,927 |
Gross profit | 11,914 | 6,196 |
Operating expenses | 8,106 | 6,592 |
Operating profit (loss) | 3,808 | (396) |
Pension expense | (41) | (27) |
Other income, net | 75 | 467 |
Interest expense | (430) | (384) |
Profit (loss) before income taxes | 3,412 | (340) |
Income tax expense | 897 | 379 |
Net earnings (loss) | 2,515 | (719) |
Less: Net earnings attributable to the non-controlling interest | 41 | 28 |
Net earnings (loss) attributable to Kewaunee Scientific Corporation | $ 2,474 | $ (747) |
Net earnings (loss) per share attributable to Kewaunee Scientific Corporation stockholders | ||
Basic (in dollars per share) | $ 0.87 | $ (0.27) |
Diluted (in dollars per share) | $ 0.86 | $ (0.27) |
Weighted average number of common shares outstanding | ||
Basic (in shares) | 2,860 | 2,807 |
Diluted (in shares) | 2,885 | 2,807 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Earnings (Loss) (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Jul. 31, 2023 | Jul. 31, 2022 | |
Statement of Comprehensive Income [Abstract] | ||
Net earnings (loss) | $ 2,515 | $ (719) |
Other comprehensive loss, net of tax: | ||
Foreign currency translation adjustments | (144) | (224) |
Other comprehensive loss | (144) | (224) |
Comprehensive earnings (loss), net of tax | 2,371 | (943) |
Less: Comprehensive income attributable to the non-controlling interest | 41 | 28 |
Comprehensive earnings (loss) attributable to Kewaunee Scientific Corporation | $ 2,330 | $ (971) |
Condensed Consolidated Statem_3
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in Capital | Treasury Stock | Retained Earnings | Accumulated Other Comprehensive Loss |
Beginning balance at Apr. 30, 2022 | $ 35,694 | $ 6,983 | $ 4,483 | $ (53) | $ 28,023 | $ (3,742) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net earnings (loss) attributable to Kewaunee Scientific Corporation | (747) | (747) | ||||
Other comprehensive loss | (224) | (224) | ||||
Stock-based compensation | (37) | 97 | (134) | |||
Ending balance at Jul. 31, 2022 | 34,686 | 7,080 | 4,349 | (53) | 27,276 | (3,966) |
Beginning balance at Apr. 30, 2023 | 37,409 | 7,084 | 5,059 | (53) | 28,761 | (3,442) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net earnings (loss) attributable to Kewaunee Scientific Corporation | 2,474 | 2,474 | ||||
Other comprehensive loss | (144) | (144) | ||||
Stock-based compensation | (309) | 185 | (494) | |||
Ending balance at Jul. 31, 2023 | $ 39,430 | $ 7,269 | $ 4,565 | $ (53) | $ 31,235 | $ (3,586) |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jul. 31, 2023 | Apr. 30, 2023 |
Current Assets: | ||
Cash and cash equivalents | $ 12,699 | $ 8,078 |
Restricted cash | 8,869 | 5,737 |
Receivables, less allowance; $560; $476, on each respective date | 42,461 | 46,081 |
Inventories | 22,126 | 21,889 |
Prepaid expenses and other current assets | 7,365 | 6,135 |
Total Current Assets | 93,520 | 87,920 |
Property, plant and equipment, at cost | 63,023 | 61,368 |
Accumulated depreciation | (45,684) | (44,966) |
Net Property, Plant and Equipment | 17,339 | 16,402 |
Right of use assets | 8,612 | 9,170 |
Other assets | 5,347 | 5,406 |
Total Assets | 124,818 | 118,898 |
Current Liabilities: | ||
Short-term borrowings | 5,054 | 3,587 |
Current portion of financing liability | 659 | 642 |
Current portion of financing lease liabilities | 86 | 85 |
Current portion of operating lease liabilities | 1,912 | 1,967 |
Accounts payable | 22,140 | 23,599 |
Employee compensation and amounts withheld | 4,903 | 4,304 |
Deferred revenue | 7,067 | 4,097 |
Other accrued expenses | 2,408 | 1,772 |
Total Current Liabilities | 44,229 | 40,053 |
Long-term portion of financing liability | 27,958 | 28,132 |
Long-term portion of financing lease liabilities | 143 | 148 |
Long-term portion of operating lease liabilities | 6,645 | 7,136 |
Accrued pension and deferred compensation costs | 3,861 | 3,546 |
Deferred income taxes | 989 | 943 |
Other non-current liabilities | 453 | 455 |
Total Liabilities | 84,278 | 80,413 |
Commitments and Contingencies | ||
Stockholders' Equity: | ||
Common stock, $2.50 par value, Authorized – 5,000 shares; Issued – 2,907 shares; 2,833 shares; – Outstanding – 2,904 shares; 2,830 shares, on each respective date | 7,269 | 7,084 |
Additional paid-in-capital | 4,565 | 5,059 |
Retained earnings | 31,235 | 28,761 |
Accumulated other comprehensive loss | (3,586) | (3,442) |
Common stock in treasury, at cost, 3 shares, on each respective date | (53) | (53) |
Total Kewaunee Scientific Corporation Stockholders' Equity | 39,430 | 37,409 |
Non-controlling interest | 1,110 | 1,076 |
Total Stockholders' Equity | 40,540 | 38,485 |
Total Liabilities and Stockholders' Equity | $ 124,818 | $ 118,898 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) shares in Thousands, $ in Thousands | Jul. 31, 2023 | Apr. 30, 2023 |
Current Assets: | ||
Allowance for receivables | $ 560 | $ 476 |
Stockholders' Equity: | ||
Common stock, par value (in dollars per share) | $ 2.50 | $ 2.50 |
Common stock, shares authorized (in shares) | 5,000 | 5,000 |
Common stock, shares issued (in shares) | 2,907 | 2,833 |
Common stock, shares outstanding (in shares) | 2,904 | 2,830 |
Treasury stock, shares (in shares) | 3 | 3 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Jul. 31, 2023 | Jul. 31, 2022 | |
Cash flows from operating activities: | ||
Net earnings (loss) | $ 2,515 | $ (719) |
Adjustments to reconcile net earnings (loss) to net cash provided by operating activities: | ||
Depreciation | 718 | 725 |
Bad debt provision | 125 | 23 |
Stock-based compensation expense | 183 | 172 |
Deferred income taxes | 46 | 23 |
Change in assets and liabilities: | ||
Receivables | 3,496 | 516 |
Inventories | (237) | (1,304) |
Accounts payable and other accrued expenses | (226) | (2,117) |
Deferred revenue | 2,970 | 10,587 |
Other, net | (1,418) | (4,221) |
Net cash provided by operating activities | 8,172 | 3,685 |
Cash flows from investing activities: | ||
Capital expenditures | (1,654) | (390) |
Net cash used in investing activities | (1,654) | (390) |
Cash flows from financing activities: | ||
Proceeds from short-term borrowings | 40,597 | 4,431 |
Repayments on short-term borrowings | (39,130) | (6,019) |
Proceeds from sale-leaseback financing transaction | 0 | 13,456 |
Payments on sale-leaseback financing transaction | (157) | (140) |
Payments on long-term lease obligations | (4) | (58) |
Net cash provided by financing activities | 1,306 | 11,670 |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | (71) | (325) |
Increase in cash, cash equivalents and restricted cash | 7,753 | 14,640 |
Cash, cash equivalents and restricted cash, beginning of period | 13,815 | 6,894 |
Cash, cash equivalents and restricted cash, end of period | $ 21,568 | $ 21,534 |
Financial Information
Financial Information | 3 Months Ended |
Jul. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Financial Information | Financial Information The unaudited interim Condensed Consolidated Financial Statements of Kewaunee Scientific Corporation (the "Company") have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading. These interim Condensed Consolidated Financial Statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of these financial statements and should be read in conjunction with the Consolidated Financial Statements and Notes included in the Company's 2023 Annual Report on Form 10-K . The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. The Condensed Consolidated Balance Sheet as of April 30, 2023 included in this interim period filing has been derived from the audited consolidated financial statements at that date, but does not include all of the information and related notes required by GAAP for complete financial statements. The preparation of the interim Condensed Consolidated Financial Statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates. |
Cash, Cash Equivalents and Rest
Cash, Cash Equivalents and Restricted Cash | 3 Months Ended |
Jul. 31, 2023 | |
Cash and Cash Equivalents [Abstract] | |
Cash, Cash Equivalents and Restricted Cash | Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents consist of cash on hand and highly liquid investments with original maturities of three months or less. During the three months ended July 31, 2023 and twelve months ended April 30, 2023, the Company had cash deposits in excess of FDIC insured limits. The Company has not experienced any losses from such deposits. Restricted cash includes bank deposits of subsidiaries used for performance guarantees against customer orders and domestic bank deposits used as collateral for an outstanding letter of credit. The Company includes restricted cash along with the cash balance for presentation in the Condensed Consolidated Statements of Cash Flows. The reconciliation between the Condensed Consolidated Balance Sheet and the Condensed Consolidated Statement of Cash Flows is as follows: July 31, 2023 April 30, 2023 Cash and cash equivalents $ 12,699 $ 8,078 Restricted cash 8,869 5,737 Total cash, cash equivalents and restricted cash $ 21,568 $ 13,815 |
Revenue Recognition
Revenue Recognition | 3 Months Ended |
Jul. 31, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Revenue Recognition | Revenue RecognitionThe Company recognizes revenue when control of a good or service promised in a contract (i.e., performance obligation) is transferred to a customer. Control is obtained when a customer has the ability to direct the use of and obtain substantially all of the remaining benefits from that good or service. The majority of the Company's revenues are recognized over time as the customer receives control as the Company performs work under a contract. However, a portion of the Company's revenues are recognized at a point-in-time as control is transferred at a distinct point in time per the terms of a contract. Disaggregated Revenue A summary of net sales transferred to customers over time and at a point in time for the periods ended July 31, 2023 and July 31, 2022 is as follows (in thousands): Three Months Ended July 31, 2023 July 31, 2022 Domestic International Total Domestic International Total Over Time $ 33,904 $ 14,419 $ 48,323 $ 35,353 $ 12,655 $ 48,008 Point in Time 1,516 — 1,516 2,115 — 2,115 Total $ 35,420 $ 14,419 $ 49,839 $ 37,468 $ 12,655 $ 50,123 Contract Balances The closing balances of contract assets included $13,621,000 in accounts receivable and $928,000 in other assets at July 31, 2023. The opening balance of contract assets arising from contracts with customers included $13,459,000 in accounts receivable and $1,191,000 in other assets at April 30, 2023. The closing and opening balances of contract liabilities included in deferred revenue arising from contracts with customers were $7,067,000 at July 31, 2023 and $4,097,000 at April 30, 2023. The timing of revenue recognition, billings and cash collections results in accounts receivable, unbilled receivables, and deferred revenue which are disclosed in the Condensed Consolidated Balance Sheets and in the Notes to the Condensed Consolidated Financial Statements. In general, the Company receives payments from customers based on a billing schedule established in its contracts. Unbilled receivables represent amounts earned which have not yet been billed in accordance with contractually stated billing terms and are included in receivables on the Condensed Consolidated Balance Sheets. Receivables are recorded when the right to consideration becomes unconditional and the Company has a right to invoice the customer. Deferred revenue relates to payments received in advance of performance under the contract. Deferred revenue is recognized as revenue as (or when) the Company performs under the contract. Approximately 100% of the contract liability balances at April 30, 2023 and July 31, 2023 are expected to be recognized as revenue during the respective succeeding 12 months. |
Inventories
Inventories | 3 Months Ended |
Jul. 31, 2023 | |
Inventory Disclosure [Abstract] | |
Inventories | Inventories The Company measures inventory using the first-in, first-out method at the lower of cost or net realizable value. Inventories consisted of the following (in thousands): July 31, 2023 April 30, 2023 Finished products $ 3,537 $ 3,412 Work in process 2,138 2,380 Raw materials 16,451 16,097 Total $ 22,126 $ 21,889 The Company's International subsidiaries' inventories were $2,902,000 at July 31, 2023 and $2,740,000 at April 30, 2023 and are included in the above tables. |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 3 Months Ended |
Jul. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company's financial instruments consist primarily of cash and equivalents, mutual funds, short-term borrowings, and the cash surrender value of life insurance policies. The carrying value of these assets and liabilities approximates their fair value. The following tables summarize the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of July 31, 2023 and April 30, 2023 (in thousands): July 31, 2023 Financial Assets Level 1 Level 2 Total Trading securities held in non-qualified compensation plans (1) $ 1,324 $ — $ 1,324 Cash surrender value of life insurance policies (1) — 1,401 1,401 Total $ 1,324 $ 1,401 $ 2,725 Financial Liabilities Non-qualified compensation plans (2) $ — $ 3,185 $ 3,185 Total $ — $ 3,185 $ 3,185 April 30, 2023 Financial Assets Level 1 Level 2 Total Trading securities held in non-qualified compensation plans (1) $ 1,105 $ — $ 1,105 Cash surrender value of life insurance policies (1) — 1,358 1,358 Total $ 1,105 $ 1,358 $ 2,463 Financial Liabilities Non-qualified compensation plans (2) $ — $ 2,910 $ 2,910 Total $ — $ 2,910 $ 2,910 (1) The Company maintains two non-qualified compensation plans which include investment assets in a rabbi trust. These assets consist of marketable securities, which are valued using quoted market prices multiplied by the number of shares owned, and life insurance policies, which are valued at their cash surrender value. (2) Plan liabilities are equal to the individual participants' account balances and other earned retirement benefits. |
Long-term Debt and Other Credit
Long-term Debt and Other Credit Arrangements | 3 Months Ended |
Jul. 31, 2023 | |
Debt Disclosure [Abstract] | |
Long-term Debt and Other Credit Arrangements | Long-term Debt and Other Credit Arrangements At April 30, 2023, advances of $3.5 million were outstanding under the Company's Revolving Credit Facility. Amounts available under the Revolving Credit Facility were $10.3 million at April 30, 2023. The borrowing rate under the Revolving Credit Facility was 9.02% as of April 30, 2023. The Company's International subsidiaries had a balance outstanding of $39,000 in short-term borrowings related to overdraft protection and short-term loan arrangements. At April 30, 2023, the Company was in compliance with all of the financial covenants under its Revolving Credit Facility. At July 31, 2023, there were $5.0 million outstanding under the Revolving Credit Facility, with remaining borrowing capacity under the Revolving Credit Facility of $8.3 million. The borrowing rate under the Revolving Credit Facility was 9.33% as of July 31, 2023. In addition, the Company's International subsidiaries have a balance outstanding of $54,000 in short-term borrowings related to overdraft protection and short-term loan arrangements. As of July 31, 2023, the Company was in compliance with all of the financial covenants under its Revolving Credit Facility. |
Sale-Leaseback Financing Transa
Sale-Leaseback Financing Transaction | 3 Months Ended |
Jul. 31, 2023 | |
Financing Liability [Abstract] | |
Sale-Leaseback Financing Transaction | Sale-Leaseback Financing Transaction On December 22, 2021, the Company entered into an Agreement for Purchase and Sale of Real Property with CAI Investments Sub-Series 100 LLC, a Nevada limited liability company (the "Buyer"), for the Company’s headquarters and manufacturing facilities located at 2700 West Front Street in Statesville, North Carolina (the "Sale Agreement"). The Sale Agreement was finalized on March 24, 2022 and coincided with the Company and CAI Investments Medical Products I Master Lessee LLC ("Lessor") entering into a lease agreement. The lease arrangement is for a 20-year term, with four renewal options of five years each. Under the terms of the lease agreement, the Company’s initial basic rent is approximately $158,000 per month, with annual increases of approximately 2% each year of the initial term. The Company accounted for the Sale-Leaseback Arrangement as a financing transaction as the lease agreement was determined to be a finance lease due to the significance of the present value of the lease payments, using a discount rate of 4.75% to reflect the Company’s incremental borrowing rate, compared to the fair value of the leased property as of the lease commencement date. In measuring the lease payments for the present value analysis, the Company elected the practical expedient to combine the lease component (the leased facilities) with the non-lease component (property management provided by the Buyer/Lessor) into a single lease component. The presence of a finance lease indicates that control of the property has not transferred to the Buyer/Lessor and, as such, the transaction was deemed a failed sale-leaseback and accounted for as a financing arrangement. As a result of this determination, the Company is viewed as having received the sale proceeds from the Buyer/Lessor in the form of a hypothetical loan collateralized by its leased facilities. The hypothetical loan is payable as principal and interest in the form of “lease payments” to the Buyer/Lessor. As such, the Company will not derecognize the property from its books for accounting purposes until the lease ends. No gain or loss was recognized under GAAP related to the Sale-Leaseback Arrangement. As of July 31, 2023, the carrying value of the financing liability was $28,617,000, net of $692,000 in debt issuance costs, of which $659,000 was classified as current on the Consolidated Balance Sheet with $27,958,000 classified as long-term. As of April 30, 2023, the carrying value of the financing liability was $28,774,000, net of $708,000 in debt issuance costs, of which $642,000 was classified as current on the Consolidated Balance Sheet with $28,132,000 classified as long-term. The monthly lease payments are split between a reduction of principal and interest expense using the effective interest rate method. Interest expense associated with the financing arrangement was $325,000 and $332,000 for the three months ended July 31, 2023 and July 31, 2022, respectively. The Company will depreciate the building down to zero over the 20-year assumed economic life of the Property so that at the end of the lease term, the remaining carrying amount of the financing liability will equal the carrying amount of the land of $41,000. Remaining future cash payments related to the financing liability as of July 31, 2023 are as follows: ($ in thousands) Remainder of 2024 $ 1,449 2025 1,970 2026 2,009 2027 2,050 2028 2,090 Thereafter 33,867 Total Minimum Liability Payments 43,435 Imputed Interest (14,818) Total $ 28,617 |
Leases
Leases | 3 Months Ended |
Jul. 31, 2023 | |
Leases [Abstract] | |
Leases | Leases The Company recognizes lease assets and lease liabilities reflecting the rights and obligations created by operating type leases for real estate and equipment in both the U.S. and internationally and financing leases for a truck and IT equipment in the U.S. At July 31, 2023 and April 30, 2023, right-of-use assets totaled $8,612,000 and $9,170,000, respectively. Operating cash paid to settle lease liabilities was $639,000 and $524,000 for the three months ended July 31, 2023 and July 31, 2022, respectively. The Company's leases have remaining lease terms of up to 9 years. In addition, some of the leases may include options to extend the leases for up to 5 years or options to terminate the leases within 1 year. Operating lease expenses were $867,000 for the three months ended July 31, 2023, inclusive of period cost for short-term leases, not included in lease liabilities, of $228,000. Operating lease expenses were $835,000 for the three months ended July 31, 2022, inclusive of period cost for short-term leases, not included in lease liabilities, of $311,000. At July 31, 2023, the weighted average remaining lease term for the capitalized operating leases was 4.9 years and the weighted average discount rate was 5.0%. For the financing leases, the weighted average remaining lease term was 2.9 years and the weighted average discount rate was 6.7%. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of those lease payments. The Company uses the implicit rate when readily determinable. Future minimum lease payments under non-cancelable leases as of July 31, 2023 were as follows: Operating Financing Remainder of fiscal 2024 $ 1,730 $ 83 2025 2,172 91 2026 1,917 71 2027 1,654 — 2028 1,127 — Thereafter 1,377 — Total Minimum Lease Payments 9,977 245 Imputed Interest (1,421) (16) Total $ 8,556 $ 229 |
Leases | Leases The Company recognizes lease assets and lease liabilities reflecting the rights and obligations created by operating type leases for real estate and equipment in both the U.S. and internationally and financing leases for a truck and IT equipment in the U.S. At July 31, 2023 and April 30, 2023, right-of-use assets totaled $8,612,000 and $9,170,000, respectively. Operating cash paid to settle lease liabilities was $639,000 and $524,000 for the three months ended July 31, 2023 and July 31, 2022, respectively. The Company's leases have remaining lease terms of up to 9 years. In addition, some of the leases may include options to extend the leases for up to 5 years or options to terminate the leases within 1 year. Operating lease expenses were $867,000 for the three months ended July 31, 2023, inclusive of period cost for short-term leases, not included in lease liabilities, of $228,000. Operating lease expenses were $835,000 for the three months ended July 31, 2022, inclusive of period cost for short-term leases, not included in lease liabilities, of $311,000. At July 31, 2023, the weighted average remaining lease term for the capitalized operating leases was 4.9 years and the weighted average discount rate was 5.0%. For the financing leases, the weighted average remaining lease term was 2.9 years and the weighted average discount rate was 6.7%. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of those lease payments. The Company uses the implicit rate when readily determinable. Future minimum lease payments under non-cancelable leases as of July 31, 2023 were as follows: Operating Financing Remainder of fiscal 2024 $ 1,730 $ 83 2025 2,172 91 2026 1,917 71 2027 1,654 — 2028 1,127 — Thereafter 1,377 — Total Minimum Lease Payments 9,977 245 Imputed Interest (1,421) (16) Total $ 8,556 $ 229 |
Earnings Per Share
Earnings Per Share | 3 Months Ended |
Jul. 31, 2023 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Earnings Per Share Basic earnings per share is based on the weighted average number of common shares outstanding during the year. Diluted earnings per share reflects the assumed exercise of outstanding options and the conversion of restricted stock units ("RSUs") under the Company's various stock compensation plans, except when RSUs and options have an antidilutive effect. There were 33,700 and 104,141 antidilutive RSUs and options outstanding at July 31, 2023 and July 31, 2022, respectively. The following is a reconciliation of basic to diluted weighted average common shares outstanding (in thousands): Three Months Ended July 31, 2023 July 31, 2022 Basic 2,860 2,807 Dilutive effect of stock options and RSUs 25 — Weighted average common shares outstanding - diluted 2,885 2,807 |
Stock Options and Stock-based C
Stock Options and Stock-based Compensation | 3 Months Ended |
Jul. 31, 2023 | |
Equity [Abstract] | |
Stock Options and Stock-based Compensation | Stock Options and Stock-based Compensation The Company recognizes compensation costs related to stock options and other stock awards granted by the Company as operating expenses over their vesting period. In June 2023, the Company granted 87,220 RSUs under the 2017 Omnibus Incentive Plan ("2017 Plan"). These RSUs include both a service and a performance component, vesting over a three-year period. The recognized expense is based upon the vesting period for service criteria and estimated attainment of the performance criteria at the end of the three-year period, based on the ratio of cumulative days of service to total days over the three-year period. The Company recorded stock-based compensation expense during the three months ended July 31, 2023 of $173,000 with the remaining estimated stock-based compensation expense of $2,032,000 to be recorded over the remaining vesting periods. The Company recorded stock-based compensation expense during the three months ended July 31, 2022 of $131,000. Directors' fees paid with shares of common stock in lieu of cash in accordance with Director compensation guidelines were $10,000 and $41,000 for the three month periods ended July 31, 2023 and July 31, 2022, respectively, and were also included in the stock-based compensation on the Condensed Consolidated Statements of Cash Flows. |
Income Taxes
Income Taxes | 3 Months Ended |
Jul. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | . Income Taxes Income tax expense of $897,000 and $379,000 was recorded for the three months ended July 31, 2023 and July 31, 2022, respectively. The effective tax rate was 26.3% and (111.5)% for the three months ended July 31, 2023 and July 31, 2022, respectively. The effective tax rate for the three months ended July 31, 2023 reflects the impact of foreign operations which are taxed at different rates than the U.S. tax rate of 21%, combined with expected current year tax expense for the Company's domestic operations in excess of the change in domestic valuation allowance required for the fiscal year. The effective tax rate for the three months ended July 31, 2022 reflected the impact of foreign operations and the recording of a valuation allowance against the deferred tax asset which resulted in the elimination of any U.S. income tax benefit for pretax losses incurred during the period. In August 2019, the Company revoked its indefinite reinvestment of foreign unremitted earnings position in compliance with ASC 740 "Income Taxes" and terminated its indefinite reinvestment of unremitted earnings assertion for the Singapore and |
Defined Benefit Pension Plans
Defined Benefit Pension Plans | 3 Months Ended |
Jul. 31, 2023 | |
Retirement Benefits [Abstract] | |
Defined Benefit Pension Plans | Defined Benefit Pension Plans The Company has non-contributory defined benefit pension plans covering substantially all domestic salaried and hourly employees. These plans were amended as of April 30, 2005; no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. There were no Company contributions paid to the plans for the three months ended July 31, 2023 and July 31, 2022. The Company assumed an expected long-term rate of return of 7.75% for the periods ended July 31, 2023 and July 31, 2022. Pension expense consisted of the following (in thousands): Three Months Ended July 31, 2023 July 31, 2022 Service cost $ — $ — Interest cost 224 322 Expected return on plan assets (328) (535) Recognition of net loss 145 240 Net periodic pension expense $ 41 $ 27 |
Segment Information
Segment Information | 3 Months Ended |
Jul. 31, 2023 | |
Segment Reporting [Abstract] | |
Segment Information | Segment Information The Company's operations are classified into two business segments: Domestic and International. The Domestic business segment principally designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, flexible systems, worksurfaces, workstations, workbenches, and computer enclosures. The International business segment, which consists of the Company's foreign subsidiaries, provides products and services, including facility design, detailed engineering, construction, and project management from the planning stage through testing and commissioning of laboratories. Intersegment transactions are recorded at normal profit margins. All intercompany balances and transactions have been eliminated. Certain corporate expenses shown below have not been allocated to the business segments. The following tables provide financial information by business segment and unallocated corporate expenses for the periods ended July 31, 2023 and 2022 (in thousands): Domestic International Corporate / Total Three months ended July 31, 2023 Revenues from external customers $ 35,420 $ 14,419 $ — $ 49,839 Intersegment revenues 51 661 (712) — Earnings (loss) before income taxes 3,623 793 (1,004) 3,412 Three months ended July 31, 2022 Revenues from external customers $ 37,468 $ 12,655 $ — $ 50,123 Intersegment revenues 796 1,621 (2,417) — Earnings (loss) before income taxes 98 1,094 (1,532) (340) |
New Accounting Standards
New Accounting Standards | 3 Months Ended |
Jul. 31, 2023 | |
Accounting Policies [Abstract] | |
New Accounting Standards | New Accounting StandardsIn June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments," which replaces the current incurred loss method used for determining credit losses on financial assets, including trade receivables, with an expected credit loss method. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2022. The Company adopted this standard in fiscal year 2024. The adoption of this standard did not have a significant impact on the Company's consolidated financial position or results of operations. |
New Accounting Standards (Polic
New Accounting Standards (Policies) | 3 Months Ended |
Jul. 31, 2023 | |
Accounting Policies [Abstract] | |
New Accounting Standards | In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments," which replaces the current incurred loss method used for determining credit losses on financial assets, including trade receivables, with an expected credit loss method. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2022. The Company adopted this standard in fiscal year 2024. The adoption of this standard did not have a significant impact on the Company's consolidated financial position or results of operations. |
Cash, Cash Equivalents and Re_2
Cash, Cash Equivalents and Restricted Cash (Tables) | 3 Months Ended |
Jul. 31, 2023 | |
Cash and Cash Equivalents [Abstract] | |
Schedule of Cash, Cash Equivalents, and Restricted Cash | The reconciliation between the Condensed Consolidated Balance Sheet and the Condensed Consolidated Statement of Cash Flows is as follows: July 31, 2023 April 30, 2023 Cash and cash equivalents $ 12,699 $ 8,078 Restricted cash 8,869 5,737 Total cash, cash equivalents and restricted cash $ 21,568 $ 13,815 |
Revenue Recognition (Tables)
Revenue Recognition (Tables) | 3 Months Ended |
Jul. 31, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Disaggregation of Revenue | A summary of net sales transferred to customers over time and at a point in time for the periods ended July 31, 2023 and July 31, 2022 is as follows (in thousands): Three Months Ended July 31, 2023 July 31, 2022 Domestic International Total Domestic International Total Over Time $ 33,904 $ 14,419 $ 48,323 $ 35,353 $ 12,655 $ 48,008 Point in Time 1,516 — 1,516 2,115 — 2,115 Total $ 35,420 $ 14,419 $ 49,839 $ 37,468 $ 12,655 $ 50,123 |
Inventories (Tables)
Inventories (Tables) | 3 Months Ended |
Jul. 31, 2023 | |
Inventory Disclosure [Abstract] | |
Summary of Inventories | Inventories consisted of the following (in thousands): July 31, 2023 April 30, 2023 Finished products $ 3,537 $ 3,412 Work in process 2,138 2,380 Raw materials 16,451 16,097 Total $ 22,126 $ 21,889 |
Fair Value of Financial Instr_2
Fair Value of Financial Instruments (Tables) | 3 Months Ended |
Jul. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Summary of Fair Value Hierarchy for Financial Assets and Liabilities Measured Recurring Basis | The following tables summarize the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of July 31, 2023 and April 30, 2023 (in thousands): July 31, 2023 Financial Assets Level 1 Level 2 Total Trading securities held in non-qualified compensation plans (1) $ 1,324 $ — $ 1,324 Cash surrender value of life insurance policies (1) — 1,401 1,401 Total $ 1,324 $ 1,401 $ 2,725 Financial Liabilities Non-qualified compensation plans (2) $ — $ 3,185 $ 3,185 Total $ — $ 3,185 $ 3,185 April 30, 2023 Financial Assets Level 1 Level 2 Total Trading securities held in non-qualified compensation plans (1) $ 1,105 $ — $ 1,105 Cash surrender value of life insurance policies (1) — 1,358 1,358 Total $ 1,105 $ 1,358 $ 2,463 Financial Liabilities Non-qualified compensation plans (2) $ — $ 2,910 $ 2,910 Total $ — $ 2,910 $ 2,910 (1) The Company maintains two non-qualified compensation plans which include investment assets in a rabbi trust. These assets consist of marketable securities, which are valued using quoted market prices multiplied by the number of shares owned, and life insurance policies, which are valued at their cash surrender value. (2) Plan liabilities are equal to the individual participants' account balances and other earned retirement benefits. |
Sale-Leaseback Financing Tran_2
Sale-Leaseback Financing Transaction (Tables) | 3 Months Ended |
Jul. 31, 2023 | |
Financing Liability [Abstract] | |
Schedule of Remaining Future Cash Payments for Financing Liability | Remaining future cash payments related to the financing liability as of July 31, 2023 are as follows: ($ in thousands) Remainder of 2024 $ 1,449 2025 1,970 2026 2,009 2027 2,050 2028 2,090 Thereafter 33,867 Total Minimum Liability Payments 43,435 Imputed Interest (14,818) Total $ 28,617 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Jul. 31, 2023 | |
Leases [Abstract] | |
Schedule of Operating Lease Maturity | Future minimum lease payments under non-cancelable leases as of July 31, 2023 were as follows: Operating Financing Remainder of fiscal 2024 $ 1,730 $ 83 2025 2,172 91 2026 1,917 71 2027 1,654 — 2028 1,127 — Thereafter 1,377 — Total Minimum Lease Payments 9,977 245 Imputed Interest (1,421) (16) Total $ 8,556 $ 229 |
Schedule of Finance Lease Maturity | Future minimum lease payments under non-cancelable leases as of July 31, 2023 were as follows: Operating Financing Remainder of fiscal 2024 $ 1,730 $ 83 2025 2,172 91 2026 1,917 71 2027 1,654 — 2028 1,127 — Thereafter 1,377 — Total Minimum Lease Payments 9,977 245 Imputed Interest (1,421) (16) Total $ 8,556 $ 229 |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 3 Months Ended |
Jul. 31, 2023 | |
Earnings Per Share [Abstract] | |
Schedule of Earnings Per Share, Basic and Diluted | The following is a reconciliation of basic to diluted weighted average common shares outstanding (in thousands): Three Months Ended July 31, 2023 July 31, 2022 Basic 2,860 2,807 Dilutive effect of stock options and RSUs 25 — Weighted average common shares outstanding - diluted 2,885 2,807 |
Defined Benefit Pension Plans (
Defined Benefit Pension Plans (Tables) | 3 Months Ended |
Jul. 31, 2023 | |
Retirement Benefits [Abstract] | |
Pension Expenses | Pension expense consisted of the following (in thousands): Three Months Ended July 31, 2023 July 31, 2022 Service cost $ — $ — Interest cost 224 322 Expected return on plan assets (328) (535) Recognition of net loss 145 240 Net periodic pension expense $ 41 $ 27 |
Segment Information (Tables)
Segment Information (Tables) | 3 Months Ended |
Jul. 31, 2023 | |
Segment Reporting [Abstract] | |
Segment Information | The following tables provide financial information by business segment and unallocated corporate expenses for the periods ended July 31, 2023 and 2022 (in thousands): Domestic International Corporate / Total Three months ended July 31, 2023 Revenues from external customers $ 35,420 $ 14,419 $ — $ 49,839 Intersegment revenues 51 661 (712) — Earnings (loss) before income taxes 3,623 793 (1,004) 3,412 Three months ended July 31, 2022 Revenues from external customers $ 37,468 $ 12,655 $ — $ 50,123 Intersegment revenues 796 1,621 (2,417) — Earnings (loss) before income taxes 98 1,094 (1,532) (340) |
Cash, Cash Equivalents and Re_3
Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands | Jul. 31, 2023 | Apr. 30, 2023 | Jul. 31, 2022 | Apr. 30, 2022 |
Cash and Cash Equivalents [Abstract] | ||||
Cash and cash equivalents | $ 12,699 | $ 8,078 | ||
Restricted cash | 8,869 | 5,737 | ||
Total cash, cash equivalents and restricted cash | $ 21,568 | $ 13,815 | $ 21,534 | $ 6,894 |
Revenue Recognition - Summary o
Revenue Recognition - Summary of Net Sales Transferred to Customers at a Point in Time and Over Time (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Jul. 31, 2023 | Jul. 31, 2022 | |
Disaggregation of Revenue [Line Items] | ||
Net sales transferred to customers | $ 49,839 | $ 50,123 |
Over Time | ||
Disaggregation of Revenue [Line Items] | ||
Net sales transferred to customers | 48,323 | 48,008 |
Point in Time | ||
Disaggregation of Revenue [Line Items] | ||
Net sales transferred to customers | 1,516 | 2,115 |
Domestic | ||
Disaggregation of Revenue [Line Items] | ||
Net sales transferred to customers | 35,420 | 37,468 |
Domestic | Over Time | ||
Disaggregation of Revenue [Line Items] | ||
Net sales transferred to customers | 33,904 | 35,353 |
Domestic | Point in Time | ||
Disaggregation of Revenue [Line Items] | ||
Net sales transferred to customers | 1,516 | 2,115 |
International | ||
Disaggregation of Revenue [Line Items] | ||
Net sales transferred to customers | 14,419 | 12,655 |
International | Over Time | ||
Disaggregation of Revenue [Line Items] | ||
Net sales transferred to customers | 14,419 | 12,655 |
International | Point in Time | ||
Disaggregation of Revenue [Line Items] | ||
Net sales transferred to customers | $ 0 | $ 0 |
Revenue Recognition - Additiona
Revenue Recognition - Additional Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Jul. 31, 2023 | Apr. 30, 2023 | |
Disaggregation of Revenue [Line Items] | ||
Contract liabilities | $ 7,067 | $ 4,097 |
Contract liability recognized as revenue percentage | 100% | 100% |
Accounts receivable | ||
Disaggregation of Revenue [Line Items] | ||
Contract assets | $ 13,621 | $ 13,459 |
Other assets | ||
Disaggregation of Revenue [Line Items] | ||
Contract assets | $ 928 | $ 1,191 |
Inventories - Summary of Invent
Inventories - Summary of Inventories (Detail) - USD ($) $ in Thousands | Jul. 31, 2023 | Apr. 30, 2023 |
Inventory Disclosure [Abstract] | ||
Finished products | $ 3,537 | $ 3,412 |
Work in process | 2,138 | 2,380 |
Raw materials | 16,451 | 16,097 |
Total | $ 22,126 | $ 21,889 |
Inventories - Additional Inform
Inventories - Additional Information (Detail) - USD ($) $ in Thousands | Jul. 31, 2023 | Apr. 30, 2023 |
Inventory [Line Items] | ||
Inventories | $ 22,126 | $ 21,889 |
International Subsidiaries | ||
Inventory [Line Items] | ||
Inventories | $ 2,902 | $ 2,740 |
Fair Value of Financial Instr_3
Fair Value of Financial Instruments - Summary of Fair Value Hierarchy for Financial Assets and Liabilities Measured Recurring Basis (Detail) $ in Thousands | Jul. 31, 2023 USD ($) CompensationPlan | Apr. 30, 2023 USD ($) CompensationPlan |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | $ 2,725 | $ 2,463 |
Financial Liabilities | $ 3,185 | $ 2,910 |
Number of non-qualified compensation plans maintained | CompensationPlan | 2 | 2 |
Non-qualified compensation plans | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Liabilities | $ 3,185 | $ 2,910 |
Trading securities held in non-qualified compensation plans | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | 1,324 | 1,105 |
Cash surrender value of life insurance policies | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | 1,401 | 1,358 |
Level 1 | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | 1,324 | 1,105 |
Financial Liabilities | 0 | 0 |
Level 1 | Non-qualified compensation plans | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Liabilities | 0 | 0 |
Level 1 | Trading securities held in non-qualified compensation plans | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | 1,324 | 1,105 |
Level 1 | Cash surrender value of life insurance policies | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | 0 | 0 |
Level 2 | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | 1,401 | 1,358 |
Financial Liabilities | 3,185 | 2,910 |
Level 2 | Non-qualified compensation plans | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Liabilities | 3,185 | 2,910 |
Level 2 | Trading securities held in non-qualified compensation plans | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | 0 | 0 |
Level 2 | Cash surrender value of life insurance policies | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Financial Assets | $ 1,401 | $ 1,358 |
Long-term Debt and Other Cred_2
Long-term Debt and Other Credit Arrangements (Details) - USD ($) $ in Thousands | Jul. 31, 2023 | Apr. 30, 2023 |
International Subsidiaries | ||
Debt Instrument [Line Items] | ||
Short-term borrowings | $ 54 | $ 39 |
Revolving Credit Facility | Credit Agreement, Mid Cap Funding IV Trust | Line of Credit | ||
Debt Instrument [Line Items] | ||
Outstanding advances under the long-term debt | 5,000 | 3,500 |
Remaining borrowing capacity | $ 8,300 | $ 10,300 |
Interest rate at period end | 9.33% | 9.02% |
Sale-Leaseback Financing Tran_3
Sale-Leaseback Financing Transaction - Narrative (Details) $ in Thousands | 3 Months Ended | ||
Jul. 31, 2023 USD ($) renewalOption | Jul. 31, 2022 USD ($) | Apr. 30, 2023 USD ($) | |
Financing Liability [Abstract] | |||
Term of agreement | 20 years | ||
Number of renewal options | renewalOption | 4 | ||
Renewal term | 5 years | ||
Initial basic monthly rent | $ 158 | ||
Annual rental increase, as a percent | 2% | ||
Discount rate | 4.75% | ||
Gain (loss) on sale leaseback agreement | $ 0 | ||
Financing liability | 28,617 | $ 28,774 | |
Debt issuance costs on financing liability | 692 | 708 | |
Current portion of financing liability | 659 | 642 | |
Long-term portion of financing liability | 27,958 | 28,132 | |
Interest expense on financing liability | 325 | $ 332 | |
Financing Liability [Line Items] | |||
Property, plant and equipment, at cost | $ 63,023 | $ 61,368 | |
Building | |||
Financing Liability [Line Items] | |||
Useful Life (in years) | 20 years | ||
Land | |||
Financing Liability [Line Items] | |||
Property, plant and equipment, at cost | $ 41 |
Sale-Leaseback Financing Tran_4
Sale-Leaseback Financing Transaction - Remaining Future Cash Payments (Details) - USD ($) $ in Thousands | Jul. 31, 2023 | Apr. 30, 2023 |
Financing Liability [Abstract] | ||
Remainder of 2024 | $ 1,449 | |
2024 | 1,970 | |
2025 | 2,009 | |
2026 | 2,050 | |
2027 | 2,090 | |
Thereafter | 33,867 | |
Total Minimum Liability Payments | 43,435 | |
Imputed Interest | (14,818) | |
Total | $ 28,617 | $ 28,774 |
Leases - Additional Information
Leases - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Apr. 30, 2023 | |
Leases [Abstract] | |||
Right of use assets | $ 8,612 | $ 9,170 | |
Operating cash paid to settle lease liabilities | $ 639 | $ 524 | |
Remaining lease term (in years) | 9 years | ||
Option to extend, term (in years) | 5 years | ||
Option to terminate, term (in years) | 1 year | ||
Operating lease, expense | $ 867 | 835 | |
Operating lease, short term, expense | $ 228 | $ 311 | |
Weighted average remaining lease term, operating lease (in years) | 4 years 10 months 24 days | ||
Weighted average discount rate, operating lease | 5% | ||
Weighted average remaining lease term, finance lease (in years) | 2 years 10 months 24 days | ||
Weighted average discount rate, finance lease | 6.70% |
Leases - Schedule of Operating
Leases - Schedule of Operating and Finance Lease Maturity (Details) $ in Thousands | Jul. 31, 2023 USD ($) |
Operating | |
Remainder of fiscal 2024 | $ 1,730 |
2025 | 2,172 |
2026 | 1,917 |
2027 | 1,654 |
2028 | 1,127 |
Thereafter | 1,377 |
Total Minimum Lease Payments | 9,977 |
Imputed Interest | (1,421) |
Total | 8,556 |
Financing | |
Remainder of fiscal 2024 | 83 |
2025 | 91 |
2026 | 71 |
2027 | 0 |
2028 | 0 |
Thereafter | 0 |
Total Minimum Lease Payments | 245 |
Imputed Interest | (16) |
Total | $ 229 |
Earnings Per Share - Additional
Earnings Per Share - Additional Information (Detail) - shares | 3 Months Ended | |
Jul. 31, 2023 | Jul. 31, 2022 | |
Earnings Per Share [Abstract] | ||
Anti-dilutive options exclude from computation of earning per share (in shares) | 33,700 | 104,141 |
Earnings Per Share Schedule of
Earnings Per Share Schedule of Earnings Per Common Share (Details) - shares shares in Thousands | 3 Months Ended | |
Jul. 31, 2023 | Jul. 31, 2022 | |
Weighted average number of common shares outstanding | ||
Basic (in shares) | 2,860 | 2,807 |
Dilutive effect of stock options and RSUs (in shares) | 25 | 0 |
Weighted average common shares outstanding - diluted (in shares) | 2,885 | 2,807 |
Stock Options and Stock-Based_2
Stock Options and Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | |
Jun. 30, 2023 | Jul. 31, 2023 | Jul. 31, 2022 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Directors' fees paid with shares of common stock in lieu of cash in accordance with Director compensation guidelines | $ 10 | $ 41 | |
2017 Plan | Restricted Stock Units (RSUs) | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Stock-based compensation expense | 173 | $ 131 | |
Remaining estimated compensation expense | $ 2,032 | ||
2017 Plan | Restricted Stock Units (RSUs) | Tranche One | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Restricted stock units granted (in shares) | 87,220 | ||
Vesting period (in years) | 3 years |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Jul. 31, 2023 | Jul. 31, 2022 | Apr. 30, 2023 | |
Income Tax Disclosure [Abstract] | |||
Income tax expense | $ 897 | $ 379 | |
Effective income tax rate | 26.30% | (111.50%) | |
Deferred tax liability, global tax exposure for unremitted earnings of international subsidiaries | $ 1,363 | $ 1,318 |
Defined Benefit Pension Plans -
Defined Benefit Pension Plans - Additional Information (Detail) - USD ($) | 3 Months Ended | |
Jul. 31, 2023 | Jul. 31, 2022 | |
Retirement Benefits [Abstract] | ||
Employer contributions | $ 0 | $ 0 |
Assumed as expected long-term rate of return (as a percent) | 7.75% | 7.75% |
Defined Benefit Pension Plans_2
Defined Benefit Pension Plans - Pension Expenses (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Jul. 31, 2023 | Jul. 31, 2022 | |
Retirement Benefits [Abstract] | ||
Service cost | $ 0 | $ 0 |
Interest cost | 224 | 322 |
Expected return on plan assets | (328) | (535) |
Recognition of net loss | 145 | 240 |
Net periodic pension expense | $ 41 | $ 27 |
Segment Information - Additiona
Segment Information - Additional Information (Detail) | 3 Months Ended |
Jul. 31, 2023 Segment | |
Segment Reporting [Abstract] | |
Number of business segments | 2 |
Segment Information (Details)
Segment Information (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Jul. 31, 2023 | Jul. 31, 2022 | |
Segment Reporting Information [Line Items] | ||
Net sales | $ 49,839 | $ 50,123 |
Intersegment revenues | 0 | 0 |
Earnings (loss) before income taxes | 3,412 | (340) |
Corporate / Eliminations | ||
Segment Reporting Information [Line Items] | ||
Net sales | 0 | 0 |
Intersegment revenues | (712) | (2,417) |
Earnings (loss) before income taxes | (1,004) | (1,532) |
Domestic Operations | Operating Segments | ||
Segment Reporting Information [Line Items] | ||
Net sales | 35,420 | 37,468 |
Intersegment revenues | 51 | 796 |
Earnings (loss) before income taxes | 3,623 | 98 |
International Operations | Operating Segments | ||
Segment Reporting Information [Line Items] | ||
Net sales | 14,419 | 12,655 |
Intersegment revenues | 661 | 1,621 |
Earnings (loss) before income taxes | $ 793 | $ 1,094 |